By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Capricor Therapeutics, Inc. 

8700 Beverly Boulevard
Davis Building - Room D-1063
Los Angeles  California  90048  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Capricor Therapeutics, Inc. Reports Second Quarter 2015 Business & Financial Highlights 8/14/2015 9:58:11 AM
Capricor Therapeutics, Inc. To Hold Second Quarter 2015 Business Update And Financial Results Conference Call On August 13, 2015 At 4:30 P.M. EDT 8/6/2015 10:32:41 AM
Capricor Therapeutics, Inc. Appoints Deborah Ascheim, M.D. As Chief Medical Officer 8/4/2015 7:16:51 AM
Capricor Therapeutics, Inc. Appoints Houman Hemmati M.D., Ph.D. To Vice President Of Medical And Clinical Development For New Therapies 6/17/2015 7:09:10 AM
Capricor Therapeutics, Inc. And CureDuchenne To Host Webinar On June 19, 2015 At 3:00 P.M. ET 6/15/2015 2:12:22 PM
Capricor Therapeutics, Inc. Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy 6/8/2015 7:34:10 AM
Capricor Therapeutics, Inc. To Participate In Two Upcoming Investor Conferences In June 5/27/2015 7:15:19 AM
Capricor Therapeutics, Inc. Reports First Quarter 2015 Financial & Business Highlights 5/13/2015 10:42:24 AM
Capricor Therapeutics, Inc. To Hold First Quarter 2015 Business Update And Financial Results Conference Call On May 12, 2015 At 4:30 P.M. EDT 5/6/2015 7:51:48 AM
Capricor Therapeutics, Inc. Granted FDA Orphan Drug Designation For Allogeneic Cardiosphere-Derived Cells For The Treatment Of Duchenne Muscular Dystrophy 4/22/2015 8:18:12 AM
123456
//-->